EUVIMEDEUVIMED entdecken
Crossref

Real world data of carfilzomib once weekly dosing in patients with relapsed and refractory multiple myeloma: a retrospective single center experience

Meral Uluköylü Mengüç, İbrahim Talha Şişman, Fatma Arıkan, Seçil Salim, Ahmet Mert Yanık, Özlem Candan, Derya Demirtaş, Hatice Gizem Günhan, Asu Fergün Yılmaz, Tayfur Toptaş, Işık Atagündüz, Ayşe Tülin Tuğlular

Journal of Current Hematology & Oncology Research · 08.08.2026 · 4 (3) · 105-109

DOI: 10.51271/jchor-0091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 08.08.2026. Verfasst von Meral Uluköylü Mengüç und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Relapsed or refractory multiple myeloma (RRMM) remains a therapeutic challenge due to treatment resistance, comorbidities, and limited options after multiple therapy lines. Carfilzomib, a second-generation proteasome inhibitor, has demonstrated efficacy when administered once weekly at 70 mg/m² in combination with dexamethasone (wKd70), offering a convenient and effective alternative to twice-weekly schedules.We conducted a retrospective analysis of 32 RRMM patients treated with wKd70 between 2018 and 2023 at a single referral center.

Methods

Thirty-two RRMM patients were analyzed retrospectively. Patients with RRMM who received at least one course of carfilzomib at a dose of 70 mg/m² (administered on days 1, 8, and 15 of 28-day cycles) in combination with dexamethasone 40 mg/week were included in the study.

Results

The median age was 57.5 years (range: 43–75), and patients had received a median of three prior therapy lines. The overall response rate (ORR) was 62.1% . Median progression-free survival (PFS) was 16 months, and median overall survival (OS) was 51 months . Prior autologous stem cell transplantation was associated with significantly improved PFS and OS. Adverse events were common but mostly mild (grades 1–2) forms.

Conclusion

Our findings support wKd70 as an effective and well-tolerated treatment option for RRMM, even in heavily pretreated patients. The favorable survival outcomes compared to historical trials suggest a role for earlier use of this regimen.

Zitieren

APA

Mengüç, M. U., Şişman, İ. T., Arıkan, F., Salim, S., Yanık, A. M., Candan, Ö., Demirtaş, D., Günhan, H. G., Yılmaz, A. F., Toptaş, T., Atagündüz, I., & Tuğlular, A. T. (2026). Real world data of carfilzomib once weekly dosing in patients with relapsed and refractory multiple myeloma: a retrospective single center experience. Journal of Current Hematology & Oncology Research, 4(3), 105-109. https://doi.org/10.51271/jchor-0091

Vancouver

Mengüç MU, Şişman İT, Arıkan F, Salim S, Yanık AM, Candan Ö, et al. Real world data of carfilzomib once weekly dosing in patients with relapsed and refractory multiple myeloma: a retrospective single center experience. Journal of Current Hematology & Oncology Research. 2026;4(3):105-109. doi:10.51271/jchor-0091

BibTeX
@article{Meng2026,
  author = {Mengüç, Meral Uluköylü and Şişman, İbrahim Talha and Arıkan, Fatma and Salim, Seçil and Yanık, Ahmet Mert and Candan, Özlem and Demirtaş, Derya and Günhan, Hatice Gizem and Yılmaz, Asu Fergün and Toptaş, Tayfur and Atagündüz, Işık and Tuğlular, Ayşe Tülin},
  title = {Real world data of carfilzomib once weekly dosing in patients with relapsed and refractory multiple myeloma: a retrospective single center experience},
  journal = {Journal of Current Hematology & Oncology Research},
  year = {2026},
  volume = {4},
  number = {3},
  pages = {105--109},
  doi = {10.51271/jchor-0091}
}
Kostenlos starten →